Phase 1/2Recruiting

RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia (RELIEF)

A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, and PRELIminary EFficacy of Percutaneous Injection of RP-008 Followed by Daily Oral Varenicline in Patients With Trigeminal Neuralgia (The RELIEF Study)

Sponsor
Kriya Therapeutics, Inc. (Industry)
Enrollment
24 planned
Conditions
Trigeminal Neuralgia
Interventions
RP-008; Varenicline tartrate
Ages
adults, older adults
Registry
NCT07596485

Full record on ClinicalTrials.gov

From the registry

The goal of this study is to evaluate if KRIYA-748 (RP-008) is safe, tolerable, and preliminary effective in treating trigeminal neuralgia (TN) when used in combination with varenicline tartrate. The study will also assess what doses of RP-008 are safe and tolerable for participants and how the severity of participants' TN pain and frequency of facial pain attacks are affected.

Primary outcomes

  • Incidence and severity of adverse events, abnormal clinical laboratory values, abnormal physical examinations, abnormal vital signs, abnormal electrocardiograms (ECGs), and suicidal ideation

History

  1. Primary completion expected

  2. Last registry update

  3. Started

  4. Registered